Perioperative & Surgical Care

Surgical site infection: prevention bundle and management

Clinical Overview and When to Suspect SSI

— Superficial incisional: skin and subcutaneous tissue only

— Deep incisional: fascia and muscle layers

— Organ/space: any anatomic space opened or manipulated during surgery (e.g., intra-abdominal abscess after colectomy, mediastinitis after CABG, joint infection after arthroplasty)

— Class I (clean): 1–2%

— Class II (clean-contaminated): 5–10%

— Class III (contaminated): 10–15%

— Class IV (dirty/infected): >20%

— New or worsening incisional pain, erythema, induration, or purulent drainage typically appearing POD 4–7 for staph/strep and POD 5–10+ for gram-negatives/anaerobes

— Fever beyond POD 3–4 (early postop fever POD 0–2 is usually atelectasis or inflammatory; SSI rarely presents that early except necrotizing infection)

— Unexpected leukocytosis, tachycardia, ileus, or failure to progress after abdominal surgery should raise concern for organ/space infection even without visible wound changes

Board pearl: Fever on POD 1 is almost never SSI — think atelectasis, drug, transfusion, or the rare clostridial/streptococcal necrotizing infection (which is a surgical emergency, not a routine SSI).

Definition (CDC/NHSN): Surgical site infection occurring within 30 days of most procedures, or within 90 days when a prosthesis/implant is left in place (joint arthroplasty, mesh, vascular graft, cardiac valve).

Three depth-based categories:

Epidemiology: SSI is the most common healthcare-associated infection in surgical patients (~20% of HAIs) and a leading driver of readmission, reoperation, and 30-day mortality after major surgery.

Wound classification predicts baseline risk:

When to suspect on the floor or in clinic:

Highest-risk procedures: colorectal, emergency laparotomy, open cardiac, vascular with groin incision, spine fusion with instrumentation, joint arthroplasty.

Presentation Patterns and Key History

— POD 0–2 (hyperacute): suspect necrotizing soft tissue infection (Clostridium perfringens, group A Strep) — pain out of proportion, crepitus, dishwater drainage, hemodynamic instability. This is not a routine SSI and demands immediate OR.

— POD 3–7: classic superficial/deep incisional SSI — Staph aureus (including MRSA), Streptococcus, coagulase-negative staph with implants

— POD >7: gram-negative rods, anaerobes, organ/space collections, deep prosthetic infections

— Weeks to months (with implant): indolent biofilm organisms — coag-neg staph, Cutibacterium acnes (shoulder arthroplasty), Candida

— Procedure details: wound class, duration, blood loss, implant placed, prophylactic antibiotic given and timing

— Host factors: diabetes and recent A1c, BMI, smoking, immunosuppression, malnutrition (albumin), prior MRSA colonization, recent hospitalization or antibiotics

— Symptom evolution: drainage character (serosanguinous vs purulent vs feculent vs bilious), wound dehiscence, fevers/chills, new GI symptoms suggesting anastomotic leak

— Functional decline: the post-discharge patient who "just isn't bouncing back" — declining PO intake, fatigue, low-grade fevers — frequently harbors an occult organ/space infection

Step 3 management: In the outpatient surgical follow-up visit, any patient with a wound issue plus systemic signs (fever, tachycardia, rising WBC) should be sent for imaging and labs rather than managed with empiric oral antibiotics — missed organ/space infections in ambulatory follow-up are a classic Step 3 transition-of-care failure.

Key distinction: Serous drainage alone in the first 48 h is usually normal; purulent or rapidly increasing drainage at any time is pathologic.

Timeline anchors the differential — always pin the postoperative day:

Targeted history elements:

Red-flag history: bilious or enteric drainage from an abdominal wound = anastomotic leak until proven otherwise; sternal click or instability after CABG = mediastinitis workup.

Physical Exam Findings and Hemodynamic Assessment

— Superficial SSI: erythema extending >1 cm beyond incision, warmth, induration, tenderness, purulent drainage from the incision; sutures/staples may "spit"

— Deep incisional SSI: fascial tenderness, wound dehiscence, fluctuance under the closure, purulence on probing

— Organ/space: often minimal external findings — abdominal distention, focal tenderness, peritoneal signs, or a draining sinus

— Vitals: fever ≥38.0°C, HR >90, RR >20, SBP trend

— Calculate qSOFA / SIRS; meet sepsis criteria → expedite resuscitation pathway

— Mental status changes in the elderly post-op patient may be the only sign of SSI-driven sepsis

— Crepitus, bullae, skin necrosis, pain out of proportion → necrotizing soft tissue infection

— Sternal instability or click after sternotomy → mediastinitis

— Bilious, enteric, or feculent drainage → anastomotic leak/enterocutaneous fistula

— Exposed mesh, hardware, or graft → deep prosthetic infection requiring source control

— Stable, isolated superficial cellulitis → outpatient

— Tachycardia + leukocytosis + organ/space concern → admit, IV antibiotics, imaging

— Hypotension, lactate >2, or AMS → ICU-level resuscitation, surgical source control within 6–12 h

CCS pearl: On the CCS case, the right first orders for a suspected SSI with systemic signs are vitals, IV access, CBC, BMP, lactate, blood cultures, wound culture, and imaging — then empiric antibiotics after cultures (don't delay antibiotics >1 h in septic patients).

Board pearl: A clean wound that looks pristine on POD 7 but the patient is febrile and tachycardic = look deeper — get CT for organ/space infection.

Local wound exam — inspect, palpate, probe:

Systemic exam — quantify the inflammatory response:

Red-flag exam findings (do not delay surgical consult):

Hemodynamic assessment drives disposition:

Diagnostic Workup — Initial Labs and Imaging

— CBC with differential: leukocytosis with left shift; leukopenia in severe sepsis is ominous

— BMP: AKI from sepsis, electrolyte derangement

— Lactate: >2 suggests hypoperfusion; >4 mandates aggressive resuscitation

— CRP and procalcitonin: CRP normally peaks POD 2–3 then declines; a secondary CRP rise after POD 4 is a sensitive flag for SSI. Procalcitonin helps distinguish bacterial from inflammatory fever and can guide antibiotic duration.

— Blood cultures × 2 before antibiotics if febrile or septic

— Wound culture: swab purulent drainage from the depth of the wound after debridement, not surface slough; send for aerobic, anaerobic, and Gram stain. For implant-associated infections, tissue or sonicate fluid cultures outperform swabs.

— Albumin/prealbumin: marks nutritional risk and impaired healing

— HbA1c and glucose: uncontrolled hyperglycemia both predisposes and complicates SSI

— Bedside ultrasound: rapid screen for superficial fluid collections, especially in obese abdominal wounds and groin incisions

— CT with IV (± oral) contrast: workhorse for organ/space SSI — abscess, anastomotic leak, mediastinitis, deep neck space infection

— MRI: preferred for spine, prosthetic joint, and soft-tissue necrotizing infection when stable

— Plain radiographs: look for subcutaneous gas (necrotizing infection) or hardware loosening/lucency around prosthetic joints

— Nuclear imaging (tagged WBC, FDG-PET): useful for chronic prosthetic and vascular graft infections when CT/MRI are equivocal

Step 3 management: Don't anchor on a normal WBC — up to 30% of organ/space SSIs present with normal WBC, especially in diabetics and the elderly. Image when clinical suspicion is high regardless of labs.

Key distinction: A rising CRP after POD 4 is more specific than fever alone for evolving SSI.

Laboratory studies:

Imaging — match modality to anatomy:

Diagnostic Workup — Advanced and Confirmatory Studies

— CT-guided aspiration/drainage of suspected abscess: both diagnostic (Gram stain, culture, cell count) and therapeutic (percutaneous drain placement). Send drain fluid for aerobic, anaerobic, fungal, and AFB cultures when indolent.

— Anastomotic leak workup: CT with oral and rectal water-soluble contrast (Gastrografin) for colorectal; upper GI contrast study for esophageal/gastric; HIDA scan for biliary leaks

— Major criteria (any one confirms): sinus tract communicating with prosthesis, or two positive cultures with same organism

— Minor criteria: elevated ESR/CRP, elevated synovial WBC, elevated synovial PMN%, positive histology, single positive culture

— Synovial alpha-defensin has high specificity for PJI

— Aspirate the joint before starting antibiotics whenever PJI is suspected; antibiotics dramatically lower yield

— LRINEC score (CRP, WBC, Hgb, Na, Cr, glucose) ≥6 raises suspicion but does not rule out NSTI

— Definitive diagnosis is surgical exploration — "dishwater" fluid, lack of bleeding, easy finger dissection through fascia

— Do not delay OR for imaging in unstable patients

— CT chest with contrast: peristernal fluid, gas, sternal dehiscence

— Sternal wound cultures and operative debridement cultures guide therapy

Board pearl: When PJI is on the differential, do not start empiric antibiotics until the joint has been aspirated unless the patient is septic — premature antibiotics make definitive microbiologic diagnosis nearly impossible and complicate downstream surgical planning.

Source-control–oriented studies:

Prosthetic joint infection (PJI) — Musculoskeletal Infection Society criteria:

Necrotizing soft tissue infection (NSTI):

Mediastinitis after cardiac surgery:

Microbiology adjuncts: 16S rRNA PCR and sonicate fluid culture for culture-negative implant infections; MRSA nares PCR to refine empiric coverage.

Risk Stratification and the Prevention Bundle

— NNIS/NHSN risk index (0–3 points): wound class III/IV, ASA ≥3, procedure duration above 75th percentile

— ACS NSQIP Surgical Risk Calculator: procedure-specific 30-day SSI risk

— Glycemic control: target HbA1c <7–8%; perioperative glucose <180 mg/dL

— Smoking cessation ≥4 weeks preop

— Nutrition: address albumin <3.0; consider 5–7 days of preop immunonutrition for major GI surgery

— MRSA decolonization (intranasal mupirocin × 5 days + chlorhexidine bathing) for cardiac, orthopedic implant, and known MRSA carriers

— Weight optimization and continued statin/beta-blocker as indicated

— Antibiotic prophylaxis: correct drug, dose within 60 min of incision (120 min for vancomycin/fluoroquinolones), redose for long cases or large blood loss, discontinue within 24 h (48 h max for cardiac)

— Skin prep with chlorhexidine-alcohol (superior to povidone-iodine for most clean cases)

— Hair removal with clippers only — never razors

— Normothermia (core temp ≥36°C) throughout the case

— Normoglycemia intra- and postoperatively

— Supplemental oxygen (FiO2 ~80%) intraop and immediate postop for intubated patients

— Maintain euvolemia, avoid unnecessary transfusion

— WHO surgical safety checklist and time-out

— Hand hygiene, sterile technique, minimize OR traffic

Step 3 management: On the ambulatory pre-op visit, the highest-yield interventions are glycemic optimization, smoking cessation counseling, and MRSA screening/decolonization for implant surgeries — these are repeatedly tested.

Validated SSI risk tools:

Modifiable preoperative risk factors (optimize in clinic before elective surgery):

The evidence-based SSI prevention bundle:

Colorectal-specific bundle: mechanical bowel prep plus oral non-absorbable antibiotics (neomycin + erythromycin or metronidazole) reduces SSI ~50%.

Pharmacotherapy — Empiric and Targeted Regimens

— Clean (cardiac, vascular, orthopedic, neuro): cefazolin 2 g (3 g if >120 kg). Add vancomycin for MRSA carriers or high-MRSA institutions.

— Clean-contaminated GI/GU: cefazolin + metronidazole, or cefoxitin/ceftriaxone+metronidazole; ertapenem for colorectal in high-risk patients

— Beta-lactam allergy: clindamycin or vancomycin ± aminoglycoside/aztreonam for gram-negatives

— Redose intraop: cefazolin every 4 h, vancomycin every 8 h, or after blood loss >1500 mL

— Superficial incisional, no systemic signs: open wound, drain, often no antibiotics needed; if cellulitis present, cephalexin or dicloxacillin; TMP-SMX, doxycycline, or clindamycin if MRSA suspected

— Deep incisional with systemic signs: IV vancomycin (MRSA coverage) + a gram-negative agent (ceftriaxone, cefepime, or piperacillin-tazobactam depending on site)

— Intra-abdominal organ/space: piperacillin-tazobactam or ceftriaxone + metronidazole; add vancomycin if MRSA risk or sepsis; carbapenem for healthcare-associated or recent broad-spectrum exposure

— Mediastinitis: vancomycin + antipseudomonal beta-lactam, plus surgical debridement

— Necrotizing soft tissue infection: vancomycin + piperacillin-tazobactam + clindamycin (clindamycin for antitoxin effect against Strep/Clostridium); add IVIG for streptococcal toxic shock

Board pearl: Source control trumps antibiotics. Undrained pus or retained necrotic tissue will not resolve with antibiotics alone — the question stem with a persistent fever despite "appropriate antibiotics" is asking you to drain or debride.

Key distinction: Prophylaxis = single perioperative dose; treatment = full therapeutic course after diagnosis.

Prophylactic antibiotic selection (single dose, pre-incision):

Empiric therapy for established SSI — tailor by site:

De-escalation: narrow within 48–72 h based on cultures; total duration typically 4–7 days after source control (STOP-IT trial supports short courses for adequately drained intra-abdominal infection).

Procedures and Source Control

— Open the wound for superficial/deep incisional SSI: remove sutures/staples over the infected portion, evacuate pus, irrigate, pack with damp gauze or place a wound vac

— Percutaneous drainage (IR-guided) for accessible abscesses ≥3 cm — first-line for most intra-abdominal organ/space SSIs in stable patients

— Operative washout for inaccessible collections, peritonitis, anastomotic leak with diffuse contamination, or failed percutaneous drainage

— Negative pressure wound therapy (wound vac) accelerates granulation and reduces dressing changes for open wounds

— Anastomotic leak: small contained leak with stable patient → drain + bowel rest + antibiotics; free leak with peritonitis → OR for washout, diversion (loop ileostomy/colostomy), or anastomotic takedown

— Mediastinitis: OR debridement, vacuum-assisted closure, delayed muscle/omental flap reconstruction

— Prosthetic joint infection:

– Acute (<3 weeks postop or <3 weeks of symptoms): DAIR — Debridement, Antibiotics, Implant Retention with polyethylene exchange

– Chronic or biofilm-mature: two-stage revision — explant + antibiotic spacer × 6 weeks IV antibiotics → reimplantation

— Infected vascular graft: explantation + extra-anatomic bypass; rifampin-soaked grafts and in situ replacement in select cases

— Mesh infection (hernia repair): synthetic mesh usually requires removal; biologic mesh may be salvageable

CCS pearl: When the case shows an undrained collection on imaging, advance the clock only after ordering IR drainage or surgical consult — the grader is watching for timely source control.

Source control is the cornerstone of SSI management:

Procedure-specific strategies:

Necrotizing soft tissue infection: emergent, wide surgical debridement within hours; repeat debridements every 24–48 h until clean margins; broad antibiotics + IVIG (for strep TSS) are adjuncts, not substitutes.

Special Populations — Elderly and Renal/Hepatic Impairment

— Present atypically: blunted fever response, delirium as the chief symptom, normal WBC despite serious infection

— Higher baseline rates of MRSA colonization, diabetes, and malnutrition → bundle adherence matters more

— Polypharmacy and drug interactions: vancomycin and aminoglycosides require careful dosing; avoid nephrotoxic combinations

— Functional decline after SSI is profound — early PT/OT, geriatrics consult, and discharge planning to SNF if needed

— Dose adjust: vancomycin (trough-based or AUC-guided 400–600 mg·h/L), piperacillin-tazobactam, cefepime, daptomycin, aminoglycosides, fluoroquinolones, TMP-SMX

— Avoid nephrotoxic combinations: vancomycin + piperacillin-tazobactam has higher AKI rates than vanc + cefepime or vanc + meropenem — favor alternatives in CKD/AKI

— Cefazolin prophylaxis is generally safe but redose at longer intervals

— Hemodialysis patients: dose vancomycin after dialysis; consider cefazolin 2 g post-HD for prophylaxis in chronic catheter use

— Reduce or avoid metronidazole, tigecycline, clindamycin, linezolid in severe hepatic dysfunction

— Monitor INR — antibiotics potentiate warfarin (especially TMP-SMX, metronidazole, fluoroquinolones)

Step 3 management: In an elderly post-op patient with new delirium and low-grade fever, order a focused infection workup including wound exam, UA, CXR, and blood cultures — delirium alone is sufficient indication to evaluate for SSI even without classic local signs.

Board pearl: In CKD, switch vanc/pip-tazo to vanc/cefepime if AKI develops — repeatedly tested antibiotic-stewardship swap.

Elderly patients (>65 years):

Renal impairment:

Hepatic impairment:

Frailty and goals of care: discuss aggressive surgical source control versus comfort-focused care in frail elderly with high operative mortality.

Special Populations — Pregnancy, Pediatrics, and Immunocompromised

— Cesarean delivery SSI rates: 3–15%; obesity, prolonged labor, chorioamnionitis, and emergency C-section are top risk factors

— Prophylaxis: cefazolin before skin incision (not after cord clamp) reduces SSI; add azithromycin for non-elective cesarean

— Chlorhexidine vaginal prep before cesarean for laboring patients

— Endometritis presents POD 2–3 with fever, uterine tenderness, foul lochia — treat with clindamycin + gentamicin (add ampicillin for GBS coverage or persistent fever)

— Avoid tetracyclines, fluoroquinolones, TMP-SMX (third trimester); cephalosporins, penicillins, clindamycin, metronidazole (2nd/3rd trimester) are generally safe

— Weight-based dosing; cefazolin 30 mg/kg for prophylaxis

— Higher rates of community-acquired MRSA in some regions → include MRSA coverage in skin and soft tissue infections

— Watch for toxic shock in pediatric postoperative patients with diffuse erythroderma and hypotension

— Broader differential including fungal (Candida, Aspergillus), atypical mycobacteria, and nocardia

— Lower threshold for biopsy and fungal cultures

— Empiric coverage often includes antifungals (echinocandin) for organ/space infections after transplant

— Hold biologics (anti-TNF, JAK inhibitors) during active infection; coordinate with rheumatology/transplant

Key distinction: Cefazolin in C-section is now given before incision, not after cord clamp — old teaching reversed by RCT evidence showing maternal SSI reduction without neonatal harm.

Board pearl: Postpartum fever POD 2–3 with uterine tenderness = endometritis, not wound infection — examine the uterus, not just the incision.

Pregnancy and postpartum:

Pediatric patients:

Immunocompromised hosts (transplant, chemotherapy, biologics, HIV):

Diabetes: maintain perioperative glucose 140–180 mg/dL; tighter control increases hypoglycemia risk without further SSI reduction.

Complications and Adverse Outcomes

— Wound dehiscence: partial (skin/subQ) vs fascial dehiscence — the latter presents with sudden gush of serosanguinous "salmon-colored" fluid and risks evisceration; requires emergent OR closure

— Incisional hernia: late consequence of deep SSI, occurring in up to 30% of infected midline laparotomies

— Chronic non-healing wound, sinus tract, enterocutaneous fistula (especially after bowel surgery)

— Hypertrophic scarring and keloid formation

— Sepsis and septic shock — leading cause of postoperative mortality

— Bacteremia and metastatic infection — endocarditis, septic arthritis, vertebral osteomyelitis (especially with S. aureus)

— Acute kidney injury from sepsis and nephrotoxic antibiotics

— Acute respiratory failure / ARDS

— Venous thromboembolism — inflammation amplifies clotting risk; continue VTE prophylaxis

— Prosthesis loosening, persistent infection requiring revision or explant

— Amputation for refractory orthopedic infections

— Graft thrombosis or rupture in vascular graft infections

— 30-day readmission — SSI is a top driver and a CMS quality measure

— Prolonged length of stay (+7–10 days), excess cost ($20,000–$30,000 per case)

— Excess mortality 2–11× depending on infection depth and organism

Step 3 management: A patient with salmon-colored serosanguinous wound drainage on POD 5–8 has fascial dehiscence until proven otherwise — cover the wound with saline-soaked gauze, abdominal binder, NPO, and call surgery for OR.

Board pearl: S. aureus bacteremia from any source mandates echocardiogram (preferably TEE) to evaluate for endocarditis and a minimum 2-week IV course.

Local complications:

Systemic complications:

Implant-related complications:

System-level outcomes:

Necrotizing infections: mortality 20–40% even with optimal care; survivors face extensive reconstruction, limb loss, and PTSD.

When to Escalate — ICU, Consult, and Inpatient Triage

— Outpatient management appropriate: superficial SSI, no systemic signs, reliable patient, able to follow up in 24–48 h, no significant comorbidity; treat with oral antibiotics ± bedside I&D

— Inpatient admission: systemic signs (fever, tachycardia, leukocytosis), organ/space infection, failed outpatient therapy, immunocompromised host, inability to tolerate PO, social barriers to follow-up

— ICU admission: sepsis with hemodynamic instability, lactate >4, vasopressor need, respiratory failure, acute organ dysfunction, necrotizing infection pre- or post-debridement

— Surgery (early and often): any deep/organ-space SSI, prosthesis involvement, dehiscence, anastomotic leak, or need for debridement — page the original operating surgeon when possible

— Infectious diseases: prosthetic infections, multidrug-resistant organisms, persistent bacteremia, complex immunocompromise, antibiotic stewardship questions

— Interventional radiology: percutaneous drainage of accessible collections

— Critical care: sepsis requiring vasopressors or organ support

— Measure lactate, blood cultures × 2 before antibiotics, broad-spectrum antibiotics within 1 h, 30 mL/kg crystalloid for hypotension or lactate ≥4, vasopressors (norepinephrine first-line) for MAP <65 despite fluids

CCS pearl: On a CCS sepsis case, the order set is lactate, cultures, antibiotics, fluids, vasopressors, ICU bed — and the timer matters. Late antibiotics cost points and outcomes.

Key distinction: "Stable" patients with organ/space SSI still belong inpatient until source control is achieved and clinical trajectory confirmed.

Disposition by severity:

Mandatory consults:

Sepsis bundle (Hour-1):

Transfers: patients with necrotizing infection at a facility without surgical capability need immediate transfer after first dose of broad-spectrum antibiotics and resuscitation — do not delay for imaging.

Key Differentials — Same-Category (Other Postoperative Infections)

— POD 2+ fever with cough, hypoxia, infiltrate; often confused with SSI when both occur

— Treat with antipseudomonal beta-lactam + vanc/linezolid for MRSA coverage

— Foley duration is the dominant risk; remove catheter as early as POD 1 when possible (SCIP measure)

— Pyuria + symptoms or new fever with positive culture → treat; asymptomatic bacteriuria generally not treated except in pregnancy or pre-urologic procedure

— Fever, chills with line in place; differential diagnosis blood cultures (line vs peripheral)

— Remove line for S. aureus, Candida, Pseudomonas, or persistent bacteremia

— Postoperative antibiotic exposure + diarrhea = check C. diff PCR/toxin

— Treat with oral vancomycin or fidaxomicin (oral metronidazole only for mild cases when other agents unavailable)

Board pearl: The "fever workup" mnemonic — 5 W's: Wind (atelectasis/pneumonia, POD 1–2), Water (UTI, POD 3–5), Wound (SSI, POD 5–7), Walking (DVT/PE, POD 5+), Wonder drugs (drug fever, anytime). Use the timeline to triage rather than reflexively imaging the wound.

Step 3 management: New diarrhea + recent antibiotics = check C. diff before assuming SSI is treatment failure.

Postoperative pneumonia (HAP/VAP):

Catheter-associated UTI (CAUTI):

Central line-associated bloodstream infection (CLABSI):

C. difficile colitis:

Postoperative endometritis (post-C-section or hysterectomy): uterine tenderness, foul lochia

Anastomotic leak vs organ/space SSI: overlapping presentations; CT with enteric contrast distinguishes

Hardware/implant infection without overt incisional findings: indolent presentation weeks to months out, often with biofilm organisms

Surgical wound seroma or hematoma: fluctuant, non-tender, no erythema; may become secondarily infected — aspirate or evacuate if symptomatic or expanding

Key Differentials — Other-Category Causes of Postoperative Fever/Pain

— Atelectasis (POD 1–2): low-grade fever, decreased breath sounds; treat with incentive spirometry, ambulation

— Venous thromboembolism (POD 3+): DVT/PE present with fever, tachycardia, dyspnea — get CTPA or LE Doppler

— Drug fever: beta-lactams, sulfonamides, anticonvulsants; eosinophilia may be present

— Transfusion reactions: febrile non-hemolytic, TRALI, hemolytic

— Adrenal insufficiency in chronic steroid users — fever, hypotension, hyponatremia

— Thyroid storm, malignant hyperthermia (intraop), neuroleptic malignant syndrome

— Hematoma resorption, pancreatitis, gout flare, cholecystitis (acalculous)

— Seroma/hematoma: fluid collection without infection; fluctuant, painless, no erythema

— Suture/stitch abscess: small, localized reaction; resolves with suture removal

— Contact dermatitis from skin adhesives, prep solutions, or dressings — erythema confined to dressing borders, pruritic rather than tender

— Pyoderma gangrenosum (postsurgical): rapidly expanding, painful, violaceous-bordered ulcer that worsens with debridement — treat with steroids, not antibiotics

Key distinction: Pyoderma gangrenosum is a critical postoperative mimicker — biopsying or debriding worsens it (pathergy). Suspect in patients with IBD, hematologic malignancy, or rheumatologic disease and a non-healing wound that fails to improve on antibiotics.

Board pearl: Postop acalculous cholecystitis classically appears in critically ill patients on TPN — RUQ ultrasound shows distended gallbladder with wall thickening but no stones; treat with percutaneous cholecystostomy.

Non-infectious causes of postoperative fever:

Non-infectious causes of wound issues:

Mimickers in immunocompromised hosts: fungal infection, atypical mycobacteria, graft-versus-host reactions, drug-induced hypersensitivity syndromes.

Secondary Prevention and Discharge Planning

— Antibiotic duration: typically complete a defined IV/PO course (5–7 days for adequately drained intra-abdominal infection per STOP-IT; longer for organ/space without full source control, prosthetic infections, or bacteremia)

— OPAT (outpatient parenteral antibiotic therapy) with PICC line for prolonged IV courses; ID follow-up within 1 week

— Oral step-down when patient is afebrile, tolerating PO, and culture-directed agent is available

— Probiotic counseling to reduce C. diff risk (modest evidence)

— Daily dressing changes with technique demonstration; written instructions in patient's language

— Signs to return: spreading erythema, fever, new drainage, dehiscence, severe pain

— Showering generally permitted after 48 h with closed incisions; avoid soaking/swimming until fully healed

— Wound vac patients: 24-hour vac company contact and clear malfunction instructions

— Diabetes: intensify glycemic management; target A1c <7%

— Smoking cessation: counseling, pharmacotherapy (varenicline, bupropion, NRT)

— Weight loss before elective implant procedures

— MRSA decolonization protocol for known carriers facing future surgery

— Address nutritional status with dietitian referral

Step 3 management: A patient discharged on OPAT needs weekly CBC, BMP, and drug-level monitoring (vancomycin trough, aminoglycoside levels) with an ID provider following — failing to arrange this is a classic Step 3 transitions-of-care error.

Discharge medication considerations:

Wound care instructions:

Long-term risk reduction for future surgery:

Vaccinations: ensure tetanus current (within 5 years for dirty wounds), influenza, pneumococcal, COVID, RSV as appropriate.

Documentation: clear handoff to PCP including infecting organism, antibiotic course, planned end date, drains in place, follow-up appointments.

Follow-Up, Monitoring, and Counseling

— First wound check in 7–14 days post-discharge with operating surgeon; sooner (3–5 days) for open wounds or wound vac

— Weekly ID visits during OPAT with labs (CBC, CMP, drug levels, CRP/ESR trend)

— PCP visit within 1–2 weeks for medication reconciliation, glycemic control, and chronic disease management

— Telehealth wound photo check-ins are increasingly used between visits

— Superficial/deep incisional: wound appearance, drainage volume and character, granulation progression

— Organ/space with drain: daily output volume and character; drain removal when <30 mL/day of non-purulent fluid and imaging confirms collection resolution

— Prosthetic infection: CRP and ESR trends over weeks to months; failure to normalize suggests persistent infection

— Bacteremia: repeat blood cultures every 48–72 h until clearance; document negative cultures before stopping IV antibiotics

— Drug toxicity: vancomycin troughs/AUC, daptomycin CPK weekly, linezolid CBC weekly (cytopenias), aminoglycoside levels and renal function

— PT/OT for deconditioning, especially after prolonged ICU stay

— Nutritional rehabilitation; consider supplements if albumin remains low

— Mental health screening — postoperative complications increase depression, anxiety, and PTSD risk

— Return-to-work and activity restrictions individualized; lifting restrictions typically 6 weeks for abdominal/thoracic surgery

CCS pearl: When advancing the clock on a post-discharge case, scheduling the wound check, ID follow-up, and labs earns points the grader expects to see.

Board pearl: Persistently elevated CRP/ESR after PJI treatment = occult persistent infection → reimage and reconsult ID.

Follow-up cadence:

Monitoring parameters by infection type:

Rehabilitation and counseling:

Quality metric tracking: SSI is reported to NHSN and tied to CMS reimbursement — institutional SSI rates drive bundle compliance audits.

Ethical, Legal, and Patient Safety Considerations

— Patients undergoing elective implant surgery must be counseled on realistic SSI risks (1–2% for joints, higher with comorbidities) and the implications of prosthetic infection — including the possibility of explantation, two-stage revision, and prolonged antibiotics

— When MRSA decolonization or HbA1c optimization is recommended preoperatively, document the discussion; proceeding with elective surgery on a poorly optimized patient may shift liability if SSI occurs

— When an SSI occurs, disclose promptly and honestly to the patient and family; "communication and resolution" programs reduce litigation and improve trust

— Document the disclosure conversation, the clinical reasoning, and the corrective plan

— SSI rates are reported to CDC NHSN; institutions face CMS reimbursement penalties under the Hospital-Acquired Condition Reduction Program for excess rates

— Some states publicly report hospital-specific SSI rates

— Retained surgical items (sponges, instruments) and wrong-site surgery are never events that predispose to SSI and trigger root-cause analysis

— Time-out and surgical safety checklist noncompliance is a documented safety lapse

— Failure to communicate active antibiotic regimens, drain plans, and culture results at discharge is a leading cause of readmission for SSI

— Use of structured discharge summaries, medication reconciliation, and warm handoffs to PCP and home health mitigates risk

— OPAT patients without scheduled ID follow-up are a known safety gap

Step 3 management: When a patient is discharged on IV antibiotics, confirm in writing the planned stop date, monitoring labs, and follow-up provider — this is the single most tested transition-of-care item for postoperative infections.

Informed consent edge cases:

Disclosure of complications (transparency and apology):

Mandatory reporting and public quality data:

Patient safety / never events:

Transition-of-care risks (Step 3 favorite):

Antimicrobial stewardship: prolonged or inappropriate prophylaxis (>24 h) drives resistance and C. difficile — a documented stewardship target.

High-Yield Associations and Rapid-Fire Facts

Board pearl: If the question stem mentions "pain out of proportion to exam" after surgery, the answer is necrotizing fasciitis → OR, never imaging or oral antibiotics.

Cefazolin timing: within 60 minutes of incision (120 min for vancomycin/fluoroquinolones).

Hair removal: clippers only, never razors — razors increase SSI risk.

Skin prep: chlorhexidine-alcohol preferred over povidone-iodine for most clean cases; iodine preferred for mucosal surfaces.

Normothermia, normoglycemia, normoxia — the "three N's" of intraoperative SSI prevention.

Glucose target perioperatively: 140–180 mg/dL; tighter increases hypoglycemia without further SSI benefit.

Smoking cessation: 4 weeks preop reduces SSI and wound complications.

MRSA decolonization: mupirocin × 5 days + chlorhexidine bathing for cardiac/orthopedic implant surgery.

Colorectal prep: mechanical bowel prep + oral non-absorbable antibiotics cuts SSI ~50%.

C-section prophylaxis: cefazolin before incision; add azithromycin for non-elective.

Necrotizing fasciitis triad: pain out of proportion, rapid progression, systemic toxicity → OR, don't wait for imaging.

LRINEC score supports but does not rule out NSTI.

Clindamycin is added to NSTI regimens for antitoxin effect against Strep/Clostridium.

Prosthetic joint biofilm organism (shoulder): Cutibacterium acnes.

Indolent prosthetic infection: coagulase-negative staph.

Acute PJI: DAIR (Debridement, Antibiotics, Implant Retention).

Chronic PJI: two-stage revision with antibiotic spacer.

Mediastinitis after sternotomy: vacuum-assisted closure + muscle/omental flap.

Anastomotic leak: CT with water-soluble contrast (Gastrografin).

Fascial dehiscence: "salmon-colored" serosanguinous drainage POD 5–8 → emergent OR.

Pyoderma gangrenosum: worsens with debridement (pathergy); treat with steroids, not antibiotics.

Postop fever 5 W's: Wind, Water, Wound, Walking, Wonder drugs.

STOP-IT trial: 4 days of antibiotics suffice for adequately drained intra-abdominal infection.

Board Question Stem Patterns

Board pearl: When two answer choices look reasonable (antibiotics vs source control), source control wins in nearly every Step 3 SSI vignette.

Pattern 1 — Prophylaxis timing: "A patient is being prepped for elective colectomy. When should cefazolin be administered?" → within 60 minutes of incision, with metronidazole added for colorectal coverage.

Pattern 2 — Wound class and bundle: Stem describes razor shaving the morning of surgery, povidone-iodine prep, prophylactic antibiotics 90 minutes before incision, and intraop hypothermia → identify the multiple bundle failures and pick the most impactful change (often clippers vs razors or pre-incision timing).

Pattern 3 — Postop fever timeline: POD 1 fever → atelectasis; POD 3–5 fever + dysuria → UTI; POD 5–7 fever + wound erythema → SSI; POD 5+ fever + leg swelling → DVT.

Pattern 4 — Pain out of proportion + crepitus: answer is emergent surgical debridement with vanc + pip-tazo + clindamycin, not CT.

Pattern 5 — Persistent fever despite antibiotics: stem describes adequate empiric antibiotics but ongoing fever and leukocytosis → answer is imaging for undrained collection / source control, not antibiotic escalation.

Pattern 6 — Prosthetic joint pain weeks to months post-op: indolent presentation → joint aspiration before antibiotics; don't start empiric coverage that obscures cultures.

Pattern 7 — Salmon-colored drainage POD 6: fascial dehiscence → cover with saline gauze, NPO, OR.

Pattern 8 — Postop diarrhea + recent antibiotics: check C. difficile, start oral vancomycin or fidaxomicin.

Pattern 9 — Non-healing ulcer in IBD patient after surgery, worsens with debridement: pyoderma gangrenosum → steroids.

Pattern 10 — Post-C-section fever POD 2–3 with uterine tenderness and foul lochia: endometritis → clindamycin + gentamicin.

Pattern 11 — Discharge planning: patient going home on IV vancomycin for deep SSI — best next step is arrange ID follow-up, weekly CBC/BMP, vancomycin trough monitoring, and home health for PICC line care.

Pattern 12 — Diabetic with elective hernia repair and A1c 10%: best preoperative step is delay surgery and optimize glycemic control.

One-Line Recap

Surgical site infection is prevented by a multimodal perioperative bundle and managed by source control plus targeted antibiotics — with the timeline of postoperative day, depth of infection, and host factors driving every diagnostic and therapeutic decision.

Board pearl: When in doubt on Step 3 — source control beats antibiotic escalation, timing beats drug choice for prophylaxis, and the postoperative day beats the wound appearance for narrowing the differential.

Prevention bundle (memorize): correct antibiotic prophylaxis within 60 min of incision and stopped within 24 h, chlorhexidine-alcohol prep, clippers (not razors), normothermia, normoglycemia (140–180 mg/dL), MRSA decolonization for implants, smoking cessation ≥4 weeks, A1c <7–8%, oral antibiotics + mechanical prep for colorectal, and pre-incision cefazolin for C-section.

Diagnosis is timeline-driven: POD 1–2 fever = atelectasis or rare necrotizing infection; POD 3–7 = classic incisional SSI (staph/strep); POD >7 = gram-negative/anaerobic organ/space; weeks-to-months with implant = biofilm organisms. Use CT with contrast for organ/space; aspirate joints before antibiotics for suspected PJI.

Management hierarchy: source control first (open wound, percutaneous drainage, OR debridement, hardware decisions) — then empiric antibiotics tailored by anatomic site and host risk (vancomycin + pip-tazo for severe; vanc + cefepime if AKI risk); de-escalate by 48–72 h and limit duration (STOP-IT: 4 days suffices when source controlled).

Transitions and follow-up are Step 3 gold: OPAT requires ID follow-up and weekly labs; wound check at 7–14 days; document antibiotic stop date; address modifiable risks before any future elective surgery; disclose complications transparently and report SSI to NHSN.